A. Dhyani
University of Milan
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by A. Dhyani.
PLOS ONE | 2015
A. Dhyani; Gianpaolo Tibolla; Andrea Baragetti; Katia Garlaschelli; Fabio Pellegatta; Liliana Grigore; Giuseppe Danilo Norata; Alberico L. Catapano
Inducible degrader of the low density lipoprotein receptor (IDOL), is an E3 ubiquitin ligase that negatively modulates low density lipoprotein receptor (LDL-R) expression. Genome-wide association studies (GWAS) indicated that genetic variants in IDOL gene contributes to variation in LDL-C plasma levels and the detailed analysis of a specific locus resulted in the identification of the functional common single nucleotide polymorphism (SNP) rs9370867 (c.G1025A, p.N342S) associates with increased LDL-R degradation and increased LDL-C levels. These findings, however, were not confirmed in two other independent cohorts and no data about the impact of this variant on atherosclerosis progression and cardiovascular risk are available. Aim of this study was to investigate the association between a functional variant in IDOL and atherosclerosis progression in an Italian general population. 1384 subjects enrolled in the PLIC study (Progression of Lesions in the Intima of Carotid) were genotyped by Q-PCR allelic discrimination and the association with anthropometric parameters, plasma lipids and the carotid intima media thickness (cIMT) and the impact on cardiovascular disease (CVD) incidence were investigated. The N342S variant was not associated with changes of the plasma lipid profile among GG, AG or AA carriers, including total cholesterol (249±21, 249±19 and 248±21 mg/dl respectively), LDL-C (158±25, 161±22 and 160±23 mg/dL), cIMT (0.74±0.14, 0.75±0.17 and 0.77±0.15 mm) and CVD incidence. In agreement, the expression of LDLR and the uptake of LDL was similar in macrophages derived from GG and AA carriers. Taken together our findings indicate that the N342S variant does not impact plasma lipid profile and is not associated with atherosclerosis progression and CVD in the general population, suggesting that other variants in the IDOL gene might be functionally linked with cholesterol metabolism.
European Heart Journal | 2018
Lorenzo Da Dalt; Massimiliano Ruscica; Fabrizia Bonacina; G. Balzarotti; A. Dhyani; Eliana S. Di Cairano; Andrea Baragetti; Lorenzo Arnaboldi; Simona De Metrio; Fabio Pellegatta; Liliana Grigore; Margherita Botta; Chiara Macchi; Patrizia Uboldi; Carla Perego; Alberico L. Catapano; Giuseppe Danilo Norata
Aims PCSK9 loss of function genetic variants are associated with lower low-density lipoprotein cholesterol but also with higher plasma glucose levels and increased risk of Type 2 diabetes mellitus. Here, we investigated the molecular mechanisms underlying this association. Methods and results Pcsk9 KO, WT, Pcsk9/Ldlr double KO (DKO), Ldlr KO, albumin AlbCre+/Pcsk9LoxP/LoxP (liver-selective Pcsk9 knock-out mice), and AlbCre-/Pcsk9LoxP/LoxP mice were used. GTT, ITT, insulin and C-peptide plasma levels, pancreas morphology, and cholesterol accumulation in pancreatic islets were studied in the different animal models. Glucose clearance was significantly impaired in Pcsk9 KO mice fed with a standard or a high-fat diet for 20 weeks compared with WT animals; insulin sensitivity, however, was not affected. A detailed analysis of pancreas morphology of Pcsk9 KO mice vs. controls revealed larger islets with increased accumulation of cholesteryl esters, paralleled by increased insulin intracellular levels and decreased plasma insulin, and C-peptide levels. This phenotype was completely reverted in Pcsk9/Ldlr DKO mice implying the low-density lipoprotein receptor (LDLR) as the proprotein convertase subtilisin/kexin Type 9 (PCSK9) target responsible for the phenotype observed. Further studies in albumin AlbCre+/Pcsk9LoxP/LoxP mice, which lack detectable circulating PCSK9, also showed a complete recovery of the phenotype, thus indicating that circulating, liver-derived PCSK9, the principal target of monoclonal antibodies, does not impact beta-cell function and insulin secretion. Conclusion PCSK9 critically controls LDLR expression in pancreas perhaps contributing to the maintenance of a proper physiological balance to limit cholesterol overload in beta cells. This effect is independent of circulating PCSK9 and is probably related to locally produced PCSK9.
Atherosclerosis | 2016
Nicola Ferri; Silvia Marchianò; Gianpaolo Tibolla; Roberta Baetta; A. Dhyani; Massimiliano Ruscica; Patrizia Uboldi; Alberico L. Catapano; Alberto Corsini
Atherosclerosis | 2015
G. Balzarotti; Gianpaolo Tibolla; Fabrizia Bonacina; C. D'Alonzo; A. Dhyani; Marco Falasca; Giuseppe Danilo Norata; A.L. Catapano
Atherosclerosis | 2014
Gianpaolo Tibolla; A. Dhyani; Andrea Baragetti; Katia Garlaschelli; Liliana Grigore; Giuseppe Danilo Norata; A.L. Catapano
Atherosclerosis | 2018
L. Da Dalt; G. Balzarotti; Massimiliano Ruscica; Fabrizia Bonacina; A. Dhyani; E. Di Cairano; Andrea Baragetti; Lorenzo Arnaboldi; S. De Metrio; Chiara Macchi; Margherita Botta; Patrizia Uboldi; Carla Perego; A.L. Catapano; Giuseppe Danilo Norata
Atherosclerosis | 2016
A. Dhyani; V.K. Pulakazhi Venu; Patrizia Uboldi; A.f. Muro; A.L. Catapano; D.G. Norata
Atherosclerosis | 2016
A. Dhyani; Andrea Baragetti; Katia Garlaschelli; Fabio Pellegatta; Liliana Grigore; D.G. Norata; A.L. Catapano
Atherosclerosis | 2016
Nicola Ferri; Gianpaolo Tibolla; A. Dhyani; Roberta Baetta; A.L. Catapano; Alberto Corsini
Atherosclerosis | 2015
A. Dhyani; V.K. Pulakazhi Venu; R. Baetta; Patrizia Uboldi; N. Ferri; A. Corsini; A.f. Muro; A.L. Catapano; Giuseppe Danilo Norata